Anticancer Metallocenes and Metal Complexes of Transition Elements from Groups 4 to 7

Molecules. 2024 Feb 11;29(4):824. doi: 10.3390/molecules29040824.

Abstract

With the progression in the field of bioinorganic chemistry, the role of transition metal complexes as the most widely used therapeutics is becoming a more and more attractive research area. The complexes of transition metals possess a great variety of attractive pharmacological properties, including anticancer, anti-inflammatory, antioxidant, anti-infective, etc., activities. Transition metal complexes have proven to be potential alternatives to biologically active organic compounds, especially as antitumor agents. The performance of metal coordination compounds in living systems is anticipated to differ generally from the action of non-metal-containing drugs and may offer unique diagnostic and/or therapeutic opportunities. In this review, the rapid development and application of metallocenes and metal complexes of elements from Groups 4 to 7 in cancer diagnostics and therapy have been summarized. Most of the heavy metals discussed in the current review are newly discovered metals. That is why the use of their metal-based compounds has attracted a lot of attention concerning their organometallic and coordination chemistry. All of this imposes more systematic studies on their biological activity, biocompatibility, and toxicity and presupposes further investigations.

Keywords: cancer diagnostics and therapy; coordination complexes; drug design; metallocenes; transition metals.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents* / chemistry
  • Antineoplastic Agents* / pharmacology
  • Coordination Complexes* / chemistry
  • Metallocenes
  • Metals, Heavy* / chemistry
  • Transition Elements* / chemistry

Substances

  • Coordination Complexes
  • Metallocenes
  • Transition Elements
  • Metals, Heavy
  • Antineoplastic Agents

Grants and funding

This research has received no external funding.